EGFR ligands synergistically increase IL‐17A‐induced expression of psoriasis signature genes in human keratinocytes via IκBζ and Bcl3

Various epidermal growth factor receptor (EGFR) ligands are highly expressed in the epidermis of psoriasis lesions, and abnormal EGFR activation appears to be involved in the pathogenesis of psoriasis. However, how EGFR signaling contributes to the development of psoriasis is unclear. Interleukin (IL)‐17A, a critical effector of the IL‐23/IL‐17A pathway, increases the expression of psoriasis signature genes in keratinocytes and plays an essential role in the pathogenesis of psoriasis by inducing IκBζ, a critical transcriptional regulator in psoriasis. In this study, we stimulated primary human keratinocytes with IL‐17A and various EGFR ligands to investigate whether EGFR ligands regulate the expression of psoriasis signature genes. In cultured normal human keratinocytes and a living skin equivalent, EGFR ligands did not induce psoriasis‐related gene expression, but significantly enhanced the IL‐17A‐mediated induction of various psoriasis signature genes, including antimicrobial peptides, cytokines, and chemokines. This was dependent on an EGFR activation‐mediated synergistic increase in IL‐17A‐induced IκBζ expression and was partially mediated by the EGFR‐dependent upregulation of Bcl3. Therefore, EGFR ligands can act as synergistic agents of IL‐17A signaling by stimulating the epidermal production of psoriasis signature genes in psoriasis lesions. This study reveals a potential mechanism by which EGFR signaling contributes to the pathogenesis of psoriasis.

[1]  K. Sayama,et al.  Nuclear IL-33 plays an important role in the suppression of filaggrin, loricrin, keratin 1, and keratin 10 by IL-4 and IL-13 in human keratinocytes. , 2021, The Journal of investigative dermatology.

[2]  S. Goriely,et al.  JNK1 Signaling Downstream of the EGFR Pathway Contributes to Aldara®-Induced Skin Inflammation , 2021, Frontiers in Immunology.

[3]  E. Simpson,et al.  Synergistic induction of IL-23 by TNFα, IL-17A, and EGF in keratinocytes. , 2020, Cytokine.

[4]  Fu-Tong Liu,et al.  FUT8 remodeling of EGFR regulates epidermal keratinocyte proliferation during psoriasis development. , 2020, The Journal of investigative dermatology.

[5]  K. Sayama,et al.  House dust mite allergens induce interleukin 33 (IL-33) synthesis and release from keratinocytes via ATP-mediated extracellular signaling. , 2020, Biochimica et biophysica acta. Molecular basis of disease.

[6]  M. Furue,et al.  Interleukin-17A and Keratinocytes in Psoriasis , 2020, International journal of molecular sciences.

[7]  K. Sayama,et al.  Improvement of psoriasis in a patient with metastatic colon cancer after treatment with panitumumab , 2019, The Australasian journal of dermatology.

[8]  S. Gaffen,et al.  IL-17 receptor–based signaling and implications for disease , 2019, Nature Immunology.

[9]  T. Litman,et al.  IκBζ is a key player in the anti-psoriatic effects of secukinumab. , 2019, The Journal of allergy and clinical immunology.

[10]  Zhuoli Zhang,et al.  Recent advances on the roles of epidermal growth factor receptor in psoriasis. , 2019, American journal of translational research.

[11]  K. Schulze-Osthoff,et al.  IκBζ is a key transcriptional regulator of IL-36–driven psoriasis-related gene expression in keratinocytes , 2018, Proceedings of the National Academy of Sciences.

[12]  A. Blauvelt,et al.  The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis , 2018, Clinical Reviews in Allergy & Immunology.

[13]  K. Sayama,et al.  Bcl‐3 induced by IL‐22 via STAT3 activation acts as a potentiator of psoriasis‐related gene expression in epidermal keratinocytes , 2018, European journal of immunology.

[14]  E. Volpe,et al.  Scanning the Immunopathogenesis of Psoriasis , 2018, International journal of molecular sciences.

[15]  T. Matsuda,et al.  IL-17A plays a central role in the expression of psoriasis signature genes through the induction of IκB-ζ in keratinocytes. , 2016, International immunology.

[16]  K. Hanazaki,et al.  Cetuximab and panitumumab in a patient with colon cancer and concomitant chronic skin disease: a potential beneficial effect on psoriasis vulgaris. , 2015, World journal of gastroenterology.

[17]  B. Kholodenko,et al.  Feedforward regulation of mRNA stability by prolonged extracellular signal-regulated kinase activity , 2015, The FEBS journal.

[18]  K. Schulze-Osthoff,et al.  I kappa B zeta is a key driver in the development of psoriasis , 2015 .

[19]  Lifang Zhao,et al.  Transcriptional regulation of CCL20 expression. , 2014, Microbes and infection.

[20]  S. Kang,et al.  Early tissue responses in psoriasis to the antitumour necrosis factor‐α biologic etanercept suggest reduced interleukin‐17 receptor expression and signalling , 2014, The British journal of dermatology.

[21]  M. Suárez-Fariñas,et al.  IL-17 Induces an Expanded Range of Downstream Genes in Reconstituted Human Epidermis Model , 2014, PloS one.

[22]  Toshiyuki Yamamoto,et al.  A case of rapid improvement of severe psoriasis during molecular-targeted therapy using an epidermal growth factor receptor tyrosine kinase inhibitor for metastatic lung adenocarcinoma. , 2012, Journal of the American Academy of Dermatology.

[23]  J. Inoue,et al.  Identification of interleukin‐1 receptor‐associated kinase 1 as a critical component that induces post‐transcriptional activation of IκB‐ζ , 2012, The FEBS journal.

[24]  K. Sayama,et al.  Interactions between myofibroblast differentiation and epidermogenesis in constructing human living skin equivalents. , 2012, Journal of dermatological science.

[25]  S. Chimenti,et al.  Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. , 2011, The Journal of investigative dermatology.

[26]  James T. Elder,et al.  EGFR and IL-1 signaling synergistically promote keratinocyte antimicrobial defenses in a differentiation-dependent manner. , 2011, The Journal of investigative dermatology.

[27]  K. Sayama,et al.  PPARγ mediates innate immunity by regulating the 1α,25-dihydroxyvitamin D3 induced hBD-3 and cathelicidin in human keratinocytes. , 2010, Journal of dermatological science.

[28]  Boris N. Kholodenko,et al.  Ligand-Specific c-Fos Expression Emerges from the Spatiotemporal Control of ErbB Network Dynamics , 2010, Cell.

[29]  L. Couderc,et al.  Improvement of psoriasis in a lung cancer patient treated with erlotinib. , 2010, European journal of dermatology : EJD.

[30]  Zhijian J. Chen,et al.  Act1, a U-box E3 Ubiquitin Ligase for IL-17 Signaling , 2009, Science Signaling.

[31]  Thomas Korn,et al.  IL-17 and Th17 Cells. , 2009, Annual review of immunology.

[32]  S. Akira,et al.  Gene-specific Requirement of a Nuclear Protein, IκB-ζ, for Promoter Association of Inflammatory Transcription Regulators* , 2008, Journal of Biological Chemistry.

[33]  Giampiero Girolomoni,et al.  The epidermal growth factor receptor system in skin repair and inflammation. , 2008, The Journal of investigative dermatology.

[34]  K. Sayama,et al.  Epiregulin, a member of the EGF family, is over-expressed in psoriatic epidermis. , 2007, Journal of dermatological science.

[35]  T. Muta,et al.  Crucial roles of binding sites for NF-kappaB and C/EBPs in IkappaB-zeta-mediated transcriptional activation. , 2007, The Biochemical journal.

[36]  P. Stork,et al.  Sustained activation of extracellular signal‐regulated kinase by nerve growth factor regulates c‐fos protein stabilization and transactivation in PC12 cells , 2006, Journal of neurochemistry.

[37]  S. Choudhary,et al.  Respiratory Syncytial Virus-Inducible BCL-3 Expression Antagonizes the STAT/IRF and NF-κB Signaling Pathways by Inducing Histone Deacetylase 1 Recruitment to the Interleukin-8 Promoter , 2005, Journal of Virology.

[38]  James T. Elder,et al.  Antagonism of Epidermal Growth Factor Receptor Tyrosine Kinase Ameliorates the Psoriatic Phenotype in Organ-Cultured Skin , 2005, Skin Pharmacology and Physiology.

[39]  B. Dallapiccola,et al.  Genomic structure, promoter characterisation and mutational analysis of the S100A7 gene: exclusion of a candidate for familial psoriasis susceptibility , 1999, Human Genetics.

[40]  James T. Elder,et al.  Human Psoriatic Skin in Organ Culture: Comparison with Normal Skin Exposed to Exogenous Growth Factors and Effects of an Antibody to the EGF Receptor , 1998, Pathobiology.

[41]  R. Davis,et al.  Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways , 1996, Journal of Molecular Medicine.

[42]  G. Nolan,et al.  The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through NF-kappa B p50 homodimers. , 1993, Genes & development.

[43]  V. Bours,et al.  The oncoprotein Bcl-3 directly transactivates through κB motifs via association with DNA-binding p50B homodimers , 1993, Cell.